Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers BASEL, Switzerland – ...
Lynch Syndrome (LS) is a common hereditary condition that greatly increases lifetime risk of colorectal, endometrial, urothelial and other cancers NOUS-209 is an off-the-shelf immunotherapy designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback